| Ethics: Investigators' interests: what should trial participants be told? | |
| | |
MedLine Citation:
|
PMID: 20125171 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Minimizing the potential adverse effects of clinical investigators' financial conflicts of interest involves, in part, determining how much of an investigator's "business" should be disclosed to participants in research studies. What should be disclosed and why? How will we know if disclosure matters? |
| | |
Authors:
|
Paul L Romain |
Publication Detail:
|
Type: News |
Journal Detail:
|
Title: Nature reviews. Rheumatology Volume: 6 ISSN: 1759-4804 ISO Abbreviation: Nat Rev Rheumatol Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-03 Completed Date: 2010-04-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500080 Medline TA: Nat Rev Rheumatol Country: United States |
Other Details:
|
Languages: eng Pagination: 70-1 Citation Subset: IM |
Affiliation:
|
Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. promain@bidmc.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biomedical Research
/
ethics Clinical Trials as Topic / ethics* Conflict of Interest* Disclosure* Humans |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rheumatoid arthritis: Can we achieve true drug-free remission in patients with RA?
Next Document: Epidemiology: Interpreting studies of interactions between RA risk factors.